Advanced specificity and sensitivity studies relative to a research use only transcription-mediated amplification-based assay for Treponema pallidum RNA detection
Trinity Krueger, Grace Kadonsky, Elizabeth Thelen, Amanda Zapp, Josephine Moore, Ahmet Muslu, Allan Pillay, Irene A. Stafford, Erik Munson

TL;DR
A new test for detecting Treponema pallidum RNA shows high sensitivity and no cross-reactivity, potentially improving syphilis diagnosis in high-risk groups.
Contribution
The study demonstrates the RUO T. pallidum TMA assay's high sensitivity and specificity in detecting T. pallidum RNA without interference from other substances.
Findings
The RUO T. pallidum TMA assay detected T. pallidum RNA with high sensitivity and no cross-reactivity from other Treponema species.
The assay's sensitivity was estimated at 421–5,707 in vitro transcript copies/mL and 9–48 T. pallidum cells/mL.
Common interfering substances like lubricant, urine, and seminal fluid did not affect assay fluorescence.
Abstract
Preliminary experimentation has suggested that a research-use-only real-time transcription-mediated amplification assay for Treponema pallidum (RUO T. pallidum TMA) yields instances of T. pallidum nucleic acid detection that coincide with non-treponemal serology in men who have sex with men (MSM) at increased risk for sexually transmitted infection. To further characterize the specificity of RUO T. pallidum TMA testing, 3,586 rectal swab specimens reported as “not detected” by the assay generated a mean endpoint FAM fluorescence of 637.5 units. Introduction of Treponema denticola, Treponema phagedenis, and Treponema refringens nucleic acid into matrices generated mean endpoint FAM fluorescence ranging from 620.7 to 633.5 units (P ≥ 0.15 versus control). Introduction of lubricant to a pooled rectal swab matrix did not result in elevated FAM fluorescence (mean endpoint value 628.3 units…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
| Non- | Number of assessments | Range of RNA concentration added (ng/mL) | Mean endpoint FAM fluorescence (95% CI) |
|---|---|---|---|
|
| 22 | 65.3–2,788.7 | 620.7 (589.4, 652.0) |
|
| 22 | 1.6–248.0 | 632.3 (599.7, 664.9) |
|
| 22 | 25.4–643.6 | 633.5 (603.9, 663.1) |
| [Specimen transport medium] | 43 | 639.8 (624.0, 655.6) |
| Additive exogenous/endogenous substance | Number of assessments | Mean endpoint FAM fluorescence (95% CI) |
|---|---|---|
| Commercial talcum powder | 84 | 654.4 (622.4, 686.4) |
| Lubricant | 83 | 628.3 (612.0, 644.6) |
| Blood (1% vol/vol) | 98 | 631.4 (616.9, 645.9) |
| Seminal fluid (10% vol/vol) | 98 | 624.0 (605.8, 642.2) |
| Urine (20% vol/vol) | 98 | 629.0 (613.5, 644.5) |
| [Rectal swab matrix] | 98 | 633.0 (618.7, 647.3) |
| Number of | Mean endpoint FAM fluorescence of | Additive exogenous/endogenous | Number of | Mean endpoint FAM fluorescence of | |
|---|---|---|---|---|---|
| 68 | 4,258.3 (3,977.4, 4,539.2) | Commercial talcum powder | 84 | 4,190.6 (3,995.6, 4,385.6) | 0.68 |
| Lubricant | 84 | 4,239.6 (4,066.5, 4,412.7) | 0.90 | ||
| 62 | 4,020.0 (3,773.3, 4,266.7) | 1% (vol/vol) blood | 90 | 4,237.1 (4,063.0, 4,411.2) | 0.14 |
| 10% (vol/vol) seminal fluid | 90 | 3,850.7 (3,632.0, 4,069.4) | 0.31 | ||
| 20% (vol/vol) urine | 90 | 3,971.4 (3,772.3, 4,170.5) | 0.76 |
| Matrix | Challenge | Limit of detection value (%) | Result (lower limit, upper limit) | McFadden |
|---|---|---|---|---|
| Specimen transport medium | 50 | 5 (3–8) cells/mL | 0.911 | |
| 95 | 48 (24–143) cells/mL | 0.911 | ||
| 50 | 221 (124–396) copies/mL | 0.927 | ||
| 95 | 5,707 (2,454–21,111) copies/mL | 0.927 | ||
| Rectal swab matrix | 50 | 3 (2, 5) cells/mL | 0.985 | |
| 95 | 9 (6, 16) cells/mL | 0.985 | ||
| 50 | 316 (none given) copies/mL | 1 | ||
| 95 | 421 (none given) copies/mL | 1 |
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSyphilis Diagnosis and Treatment · Reproductive tract infections research · Sex work and related issues
INTRODUCTION
Surveys have revealed that primary and secondary syphilis rates among men who have sex with men (MSM) are 100 times higher than those among men who have sex with women (1). While combination treponemal and non-treponemal serology continues to be the laboratory diagnostic reference standard for evidence of Treponema pallidum infection, molecular diagnostics can contribute adjunctive or additive data toward a laboratory diagnosis of syphilis. Indeed, a number of studies have described nucleic acid amplification tests for the detection of T. pallidum-specific nucleic acid from genital swab specimens collected from both genders (2–4).
As it pertains to MSM, non-invasive rectal swab screening has been demonstrated in numerous venues to be an effective means of detecting sexually transmitted infection (STI) agents (5–7). Specific investigations into diagnostic yield from self-collected rectal swabs have revealed high levels of concordance with provider collection (8, 9). In a preliminary study, Zapp et al. (10) performed a serologic correlation of a transcription-mediated amplification (TMA)-based research-use-only (RUO) assay for detection of T. pallidum 23S ribosomal (r)RNA from self-collected rectal swab specimens of an MSM cohort, with all T. pallidum-detected specimens coinciding with reactive non-treponemal results.
Because the inherent nature of this anatomic site collection may be fraught with abundances of microbiota (including normal flora treponemes [11]), cross-reacting substances, interfering substances, potentially autofluorescence substances, and nucleic acid amplification inhibitors, we sought to perform additional ex vivo challenges of this RUO assay to confirm test specificity. Moreover, experiments were undertaken to fully elucidate assay sensitivity.
MATERIALS AND METHODS
RUO T. pallidum TMA assay
Proprietary reagents were supplied by Hologic, Inc. (San Diego, CA). A total of 50 μL volume of target capture oligonucleotide, T7 initiator oligonucleotide, T7- and non-T7-based primer oligonucleotides specific to 23S rRNA sequences of T. pallidum, and probe oligonucleotide were added by the end-user into general-purpose target capture, amplification, enzyme, or FAM fluorescence-based promoter reagents (12). Automated direct-tube sample processing of the RUO assay occurred on the Panther system utilizing real-time TMA in tandem with fluorescence emission detection (13). System software recorded assay-specific FAM fluorescence values at specific intervals throughout the assay. Analyzer-programmed parameters for a positive result included a FAM fluorescence signal emergence time (T-time) cutoff value of 40 minutes and relative fluorescent unit output exceeding 1,000 units.
Rectal swab specimens
The study utilized remnant rectal swab specimens that were collected using the Aptima Multitest Swab Specimen Collection Kit (Hologic) as part of routine clinical testing and research studies. The current investigation was approved by the Marquette University Institutional Review Board. Rectal swabs were previously submitted for routine performance of a Chlamydia trachomatis- and Neisseria gonorrhoeae-specific commercial FDA-cleared TMA assay, as well as a laboratory-verified Mycoplasma genitalium TMA assay (6, 7). All specimens were maintained at 2°C–30°C prior to testing. All specimens were tested within 30 days of collection.
Rectal swab matrix
Residual rectal swab specimen transport medium from specimens that failed to generate significant T-time and qualitative result data, upon performance of RUO T. pallidum TMA, was pooled into a 50 mL conical vial and utilized as a matrix for subsequent experimentation relative to interfering/inhibitory substances and for limit of detection studies.
RNA extraction from non-T. pallidum treponemal bacteria
RNA was extracted from Treponema denticola, Treponema phagedenis, and Treponema refringens using the PureLink RNA minikit (Life Technologies, Carlsbad, CA). RNA concentrations were estimated with the Trizol-Qubit method using a Qubit RNA HS/BR Assay Kit (ThermoFisher Scientific, Waltham, MA) following the manufacturer’s instructions.
T. pallidum whole organism and in vitro RNA transcript material
Control materials used in these experiments included synthetic in vitro RNA transcripts corresponding to region 1 of T. pallidum 23S rRNA, which were diluted in Aptima specimen transport medium (Hologic). Whole-organism T. pallidum (Nichols strain) and Treponema endemicum were propagated in rabbit testes, quantitated by darkfield microscopy, and diluted in Aptima specimen transport medium.
Inhibitory/interfering substances
In a first set of experiments, one swab tip-full of commercial gynecologic lubricant was added to the bottom of clean, conical-bottom specimen tubes, followed by 450 μL aliquots of rectal swab matrix. In analogous fashion, one small spatula tip-full of commercial talcum powder was added to the bottom of clean, conical bottom specimen tubes, followed by 450 μL aliquots of rectal swab matrix. A subset of tubes within each treatment group was spiked with a 100 μL aliquot of T. pallidum Nichols strain organism suspension at a concentration of 10^4^/mL. In a second set of experiments, human whole blood, seminal fluid, or urine was dispensed into the bottom of clean, conical bottom specimen tubes, followed by appropriate volumes of rectal swab matrix to create ratios of 1% whole blood, 10% seminal fluid, and 20% urine. Total volumes devised in these experiments were 3,000 μL. A subset of tubes within each treatment group was spiked with a 300 μL aliquot of T. pallidum Nichols strain organism suspension at a concentration of 10^4^/mL. All tubes were subjected to RUO T. pallidum TMA and processed by Panther direct tube sampling.
In a third set of experiments, non-T. pallidum Treponema spp. RNA was added to Aptima Multitest Swab Specimen Collection tubes containing 2.9 mL of Aptima sample transport medium (Hologic) for RUO T. pallidum TMA testing by direct tube sampling on the Panther system. Experimentation was undertaken with multiple volume deliveries; maximum RNA concentrations tested were 2,788 ng/mL for T. denticola, 248.0 ng/mL for T. phagedenis, and 643.6 ng/mL for T. refringens. With respect to all experimentation described in this section, generated data were compared to respective control tubes containing solely rectal swab matrix or Aptima specimen transport medium.
Limit of detection experiments
T. pallidum whole organism stocks and in vitro RNA transcript solutions were serially diluted 10-fold in separate diluents of Aptima specimen transport medium and rectal swab matrix. All samples were subjected to RUO T. pallidum TMA and processed by Panther direct tube sampling. Generated data were compared to respective control tubes containing solely Aptima specimen transport medium or rectal swab matrix.
Statistical analysis
Differences in mean endpoint FAM fluorescence were analyzed by the t-test for independent samples. Positivity results were analyzed by probit analysis (normal model) to determine the 50% and 95% limit of detection values. An a priori decision was made to examine statistical significance using a two-tailed test with an alpha level of 0.05.
RESULTS
Specificity and cross-reactivity assessment of RUO T. pallidum TMA
Analytical specificity of RUO T. pallidum TMA was first assessed by testing specimen transport medium in the absence or presence of various concentrations of T. denticola-, T. phagedenis-, and T. refringens-specific RNA (Table 1). None of the specimen transport medium tubes spiked with RNA samples demonstrated false-positive results for RUO T. pallidum TMA. These non-T. pallidum Treponema spp. exhibited mean endpoint FAM fluorescence values ranging from 620.7 to 633.5 units (P ≥ 0.22 versus specimen transport medium; Table 1). As part of an analyzer interpretation algorithm, endpoint FAM fluorescence values exceeding 1,000 units contribute to a positive result for RUO T. pallidum TMA.
In ancillary experimentation, challenge of RUO T. pallidum TMA with T. endemicum at a concentration of 10^1^ cells/mL produced significant FAM fluorescence. Thirteen such replicates yielded a mean endpoint FAM fluorescence value of 3,949.9 units (95% CI 3,182.7, 4,717.1; P < 0.0002 versus specimen transport medium).
Secondly, the introduction of exogenous and endogenous substances to the rectal swab matrix was performed, in part, to determine if the substances generate autofluorescence. In a point prevalence study, 3,586 rectal swab specimens exhibited a mean endpoint FAM fluorescence value of 637.5 units (95% CI 635.2–639.8) by RUO T. pallidum TMA. Addition of commercial talcum powder, gynecologic lubricant, 1% blood, 10% seminal fluid, or 20% urine to pooled rectal swab matrix did not result in increased mean endpoint FAM fluorescence (mean values of individual substances ranged from 624.0 to 654.4 units) as compared to control rectal swab matrix (P ≥ 0.20; Table 2). Moreover, the addition of these exogenous and endogenous substances to suspensions of the T. pallidum Nichols strain resulted in exponential FAM fluorescence kinetic profiles that were similar to those from amplification of T. pallidum alone. Specifically, spiking T. pallidum Nichols strain to tubes containing powder and lubricant (i.e., non-liquid exogenous substances) resulted in mean endpoint FAM fluorescence values of 4,190.6 and 4,239.6 units, respectively (P ≥ 0.68; Table 3), as tested by RUO T. pallidum TMA. Analogous addition of liquid-based endogenous substances (blood, seminal fluid, urine) resulted in mean endpoint FAM fluorescence values that were similar to those of T. pallidum rRNA amplification alone (P ≥ 0.14).
RUO T. pallidum TMA limit of detection
Further characterization of RUO T. pallidum TMA entailed serial 10-fold dilutions of in vitro transcript and whole cell T. pallidum in mock and clinical matrices. For titrations in pooled rectal swab matrix, positive results were reported in all replicates tested at concentrations ≥1,000 copies/mL of in vitro 23S rRNA transcript (n = 30 replicates for each of three concentrations tested) and in >97% of additional replicates tested at concentrations ≥10 T. pallidum cells/mL (n ≥ 35 replicates for two concentrations tested). For titrations in specimen transport medium, positive results were reported in >96% of replicates tested at concentrations ≥10,000 copies/mL of in vitro 23S rRNA transcript (n = 30 replicates for each of two concentrations tested) and in 70% of replicates tested at a concentration of 1,000 copies/mL. Relative to rectal swab matrix, T-times were observed in >82% of replicates tested at concentrations ≥10 T. pallidum cells/mL (n ≥ 32 replicates for each of two concentrations tested) and in 8.6% of replicates tested at a concentration of 1 T. pallidum cell/mL (35 replicates tested).
Via probit analysis, these data translated into limits of detection that were found to be lower within the pooled rectal swab matrix (Table 4). As one example, the 95% limit of detection value for ex vivo detections of whole cell T. pallidum in rectal swab matrix was 9 cells/mL as compared to 48 cells/mL in specimen transport medium. In a similar fashion, 95% limit of detection values for in vitro challenges of 23S rRNA were 421 copies/mL and 5,707 copies/mL in rectal swab and specimen transport matrices, respectively.
DISCUSSION
Early studies of RUO T. pallidum TMA sought to integrate organism detection from MSM patients with syphilis serology and clinical presentation. Golden et al. (14) performed the assay on both rectal and pharyngeal mucosal swab specimens and reported that within 24 patients who met study-defined criteria for diagnosis of syphilis, one-half had a positive result from either site of collection. Within these 12 patients, there were two who tested positive by the assay in the absence of both a reactive RPR result and a clinical diagnosis of syphilis. Zapp et al. (10) corroborated a portion of these findings in an independent MSM cohort by demonstrating positive RUO T. pallidum TMA results from rectal swab specimens of five participants with non-treponemal serologic seroconversion. In one additional patient, RUO T. pallidum TMA detection was accompanied by an RPR titer that subsequently showed a fourfold reduction after 120 days.
The aforementioned clinical data imply that RUO T. pallidum TMA possesses robust analytic sensitivity. This paradigm is not without precedent, as other publications have noted increased sensitivity of TMA-based assays over those of other nucleic acid amplification modalities specific to C. trachomatis (15), N. gonorrhoeae (16), Trichomonas vaginalis (17), and M. genitalium (18). Improved performance in a clinical setting has also been documented with hepatitis C virus TMA (19). In our experimentation, the introduction of potentially inhibitory substances such as urine, lubricant, and blood to specimen transport medium tubes containing known concentrations of T. pallidum Nichols strain (Table 3) did not result in a significant reduction of mean endpoint FAM fluorescence. The prospect of a concomitant lower limit of detection for TMA was confirmed by probit analysis (95% parameter; Table 4), which revealed T. pallidum whole organism detection at a range of 9–48 cells, with one set of determinations made in a clinical matrix. These data hold particular significance when considering the biology of T. pallidum infection. Mahoney and Bryant (20) reported that T. pallidum applied to mucous membranes could be localized to deep tissue within 2 hours. In attempts to detect the agent of syphilis by non-serologic means (i.e., mucocutaneous direct detection), one must be cognizant of potentially low-level residual organisms present at the original site of acquisition. TMA-based diagnostics may be indicated for such scenarios. Additional studies will be necessary to determine the potential utility of RUO T. pallidum TMA in early screening of asymptomatic (both female and male) patient populations who may be at increased risk for T. pallidum infection.
Potential increased assay analytic sensitivity, by way of a fluorescence-based detection system, could be explained by potential cross-reactivity and interfering substances. To test this hypothesis, specimen transport medium tubes were mock challenged with nucleic acids from three non-T. pallidum Treponema spp. that could simulate inhabitants of mucocutaneous tissues in humans. Mean endpoint FAM fluorescence values (none of which exceeded 634 units; Table 1) were not significantly altered from those derived from analysis of control material (P ≥ 0.22). Endpoint FAM fluorescence values exceeding 1,000 units contribute to a RUO T. pallidum TMA result of positive. One non-T. pallidum Treponema spp. that did not follow this RUO T. pallidum TMA specificity paradigm was the endemic treponematosis agent T. endemicum. However, these findings were not surprising since agents of endemic treponematoses have been demonstrated to be >99.7% identical to T. pallidum at the genetic level (21). Moreover, clinical laboratorians are cognizant of the fact that T. endemicum, the etiologic agent of endemic syphilis (bejel), has a typical distribution in dry, hot nations, with major localization in the Sahelian region of Africa (22).
With respect to the possibility of non-specific fluorescence or autofluorescence generation in the context of our study, Bottiroli et al. (23) reported natural fluorescence ex vivo in both normal and neoplastic human colonic tissue. However, data presented in Table 2 revealed a stable mean endpoint FAM fluorescence generated by RUO T. pallidum TMA in 98 assessments of pooled rectal swab matrix; moreover, addition of several exogenous or endogenous substances (including powder and seminal fluid) to known rectal swab matrices not exhibiting FAM fluorescence did not generate non-specific FAM fluorescence (P ≥ 0.20).
The interpretation of findings presented in this report is not without limitations. One major limitation relates to potential variability in run-to-run fluorescence output, even in background matrix material. This potential is hypothetically amplified by the fact that the RUO T. pallidum TMA is constructed in 100-test kits, meaning that multiple user-constructed kits were necessary to complete work in this investigation. This potential variability relative to kit construction is inherent to other commercially available TMA assays and may actually be generalizable to routine performance of the assay. Furthermore, larger n values for treatment groups executed in this study would mitigate variability to a degree for valid statistical analysis. Finally, data from the talcum powder and lubricant experiments may not extrapolate to similar products that have different chemical compositions.
In conclusion, RUO T. pallidum TMA has the potential to improve laboratory diagnosis of syphilis, particularly in patients at increased risk for STIs. The high analytic sensitivity and lack of cross-reactivity of the RUO T. pallidum TMA can facilitate other laboratories exploring the use of the assay in a research setting. Further clinical correlation in MSM at increased STI risk, as well as from female genital specimens (24), is warranted.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1de Voux A, Kidd S, Grey JA, Rosenberg ES, Gift TL, Weinstock H, Bernstein KT. 2017. State-specific rates of primary and secondary syphilis among men who have sex with men — United States, 2015. MMWR Morb Mortal Wkly Rep 66:349–354. doi:10.15585/mmwr.mm 6613 a 128384130 PMC 5657910 · doi ↗ · pubmed ↗
- 2Aung ET, Fairley CK, Williamson DA, Azzato F, Towns JM, Wigan R, Chow EPF, Chen MY. 2023. Treponema pallidum detection at asymptomatic oral, anal, and vaginal sites in adults reporting sexual contact with persons with syphilis. Emerg Infect Dis 29:2083–2092. doi:10.3201/eid 2910.23066037703891 PMC 10521609 · doi ↗ · pubmed ↗
- 3Labrandero Hoyos C, Peñuelas Leal R, Casanova Esquembre A, Lorca Spröhnle J, Echevarría AG, Magdaleno Tapial J, Martinez-Domenech Á, Mochón MDO, Hernández Bel P. 2023. Diagnostic value of Treponema pallidum PCR test in real practice. Australas J Dermatol 64:e 51–e 56. doi:10.1111/ajd.1396436598263 · doi ↗ · pubmed ↗
- 4Flipse J, Niekamp A-M, Dirks A, Dukers-Muijrers N, Hoebe C, Wolffs P, van Loo IHM. 2023. Refining timely diagnosis of early syphilis by using Treponema pallidum PCR or Ig M immunoblotting next to conventional serology for syphilis. J Clin Microbiol 61:e 0011223. doi:10.1128/jcm.00112-2337222630 PMC 10281170 · doi ↗ · pubmed ↗
- 5Van Der Pol B, Chernesky M, Gaydos CA, Hook EW 3rd, Joseph AM, Christensen K, Arcenas R, Boutwell A, Wiesenfeld HC, Taylor SN, Mayer KH, Golden MR, Moncada J, Jang D, Schachter J Ex Gen Study Group Kristal Aaron University of Alabama at Birmingham, Paula Dixon University of Alabama at Birmingham, Karen Eckert Becton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions, Shiaolan Y. Ho Abbott, Medical Affairs, Michael Lewinski Roche Diagnostic Solutions, Kevin Luk Roche Diagnos · doi ↗ · pubmed ↗
- 6Munson E, Reynoso A, Pass M, Buehler K, Ryan D, Clifford A, Morgan E, Mustanski B. 2020. Comprehensive molecular screening in a cohort of young men who have sex with men and transgender women: effect of additive rectal specimen source collection and analyte testing. Sex Transm Dis 47:748–753. doi:10.1097/OLQ.000000000000124433045163 PMC 9624201 · doi ↗ · pubmed ↗
- 7Munson E, Wenten D, Jhansale S, Schuknecht MK, Pantuso N, Gerritts J, Steward A, Munson KL, Napierala M, Hamer D. 2017. Expansion of comprehensive screening of male sexually transmitted infection clinic attendees with Mycoplasma genitalium and Trichomonas vaginalis molecular assessment: a retrospective analysis. J Clin Microbiol 55:321–325. doi:10.1128/JCM.01625-1627629896 PMC 5228246 · doi ↗ · pubmed ↗
- 8Hockman BE, Qi M, Rotblatt H, Borenstein L, Flynn RA, Muldrow RA, Rajagopalan S, Greene DN. 2024. Overcoming analytical and preanalytical challenges associated with extragenital home collected STI specimens. J Clin Microbiol 62:e 0031124. doi:10.1128/jcm.00311-2438836570 PMC 11250113 · doi ↗ · pubmed ↗
